This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MTCR Metacrine (MTCR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Metacrine Stock (NASDAQ:MTCR) 30 days 90 days 365 days Advanced Chart Get Metacrine alerts:Sign Up Key Stats Today's Range$0.58▼$0.5950-Day Range$0.55▼$0.5952-Week Range$0.30▼$0.59Volume83,889 shsAverage Volume225,834 shsMarket Capitalization$24.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMetacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More… Receive MTCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter. Email Address MTCR Stock News HeadlinesU.S. sending powerful defense system to Israel, deepening its involvement in the conflictNovember 11, 2024 | nbcnews.comNorth Korea: 6 Experts on How We Can Solve the ProblemOctober 25, 2024 | time.com[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trader Jonathan Rose has discovered a strange anomaly… hidden deep inside the $300 trillion CBOE. He calls it the "Big-Money Tell." And it gives him a way to invest just before potential major AI-related announcements send stocks flying. Now, Jonathan says the next big AI-related announcement could be coming soon. And you can use his "tell" to invest BEFORE it happens… starting as soon as 7 days from now. How?June 16, 2025 | Masters in Trading (Ad)'Iran made a big mistake': Israel promises revenge after missile attackOctober 4, 2024 | usatoday.comUkraine summons Iranian diplomat as Tehran denies missile transfer to RussiaSeptember 12, 2024 | reuters.comRussia strikes Ukraine's power grid in 'most massive' attack of warAugust 28, 2024 | reuters.comCuban regime’s reported return to meddling in US elections a ‘badge of honor’ for targeted criticsAugust 1, 2024 | foxnews.comUS says China is boosting Russia's war machine in UkraineApril 17, 2024 | reuters.comSee More Headlines MTCR Stock Analysis - Frequently Asked Questions How were Metacrine's earnings last quarter? Metacrine, Inc. (NASDAQ:MTCR) announced its quarterly earnings data on Thursday, May, 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.06. When did Metacrine IPO? Metacrine (MTCR) raised $84 million in an initial public offering on Wednesday, September 16th 2020. The company issued 6,500,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What other stocks do shareholders of Metacrine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Metacrine investors own include Outlook Therapeutics (OTLK), Plug Power (PLUG), Advanced Micro Devices (AMD), Salesforce (CRM), Fisker (FSR), Micron Technology (MU) and 9 Meters Biopharma (NMTR). Company Calendar Last Earnings5/13/2021Today6/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MTCR CIK1634379 Webwww.metacrine.com Phone858-369-7800FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-84.88% Return on Assets-59.33% Debt Debt-to-Equity Ratio0.34 Current Ratio12.15 Quick Ratio12.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book0.43Miscellaneous Outstanding Shares42,570,000Free Float36,695,000Market Cap$24.75 million OptionableNot Optionable Beta-0.73 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:MTCR) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metacrine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metacrine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
